X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 58 filers reported holding X4 PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,473 | -43.8% | 17,865 | 0.0% | 0.01% | -28.6% |
Q2 2023 | $34,658 | +11.5% | 17,865 | -50.0% | 0.01% | 0.0% |
Q1 2023 | $31,085 | -12.4% | 35,730 | 0.0% | 0.01% | -12.5% |
Q4 2022 | $35,480 | -41.8% | 35,730 | 0.0% | 0.01% | -38.5% |
Q3 2022 | $61,000 | +79.4% | 35,730 | 0.0% | 0.01% | +85.7% |
Q2 2022 | $34,000 | -46.0% | 35,730 | 0.0% | 0.01% | -36.4% |
Q1 2022 | $63,000 | -23.2% | 35,730 | 0.0% | 0.01% | -15.4% |
Q4 2021 | $82,000 | -56.6% | 35,730 | 0.0% | 0.01% | -58.1% |
Q3 2021 | $189,000 | -18.5% | 35,730 | 0.0% | 0.03% | -11.4% |
Q2 2021 | $232,000 | -62.3% | 35,730 | -50.0% | 0.04% | -34.0% |
Q1 2021 | $616,000 | +167.8% | 71,460 | +100.0% | 0.05% | +17.8% |
Q4 2020 | $230,000 | -5.0% | 35,730 | 0.0% | 0.04% | +4.7% |
Q3 2020 | $242,000 | -27.3% | 35,730 | 0.0% | 0.04% | -27.1% |
Q2 2020 | $333,000 | -6.7% | 35,730 | 0.0% | 0.06% | -36.6% |
Q1 2020 | $357,000 | -6.5% | 35,730 | 0.0% | 0.09% | +55.0% |
Q4 2019 | $382,000 | – | 35,730 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 6,247,500 | $6,809,775 | 2.18% |
Bain Capital Life Sciences Investors, LLC | 15,960,588 | $17,397,041 | 1.94% |
Stonepine Capital Management, LLC | 5,273,685 | $5,748,317 | 1.91% |
NEA Management Company, LLC | 14,986,793 | $16,335,604 | 1.26% |
Sio Capital Management, LLC | 2,599,003 | $2,832,913 | 0.88% |
New Leaf Venture Partners, L.L.C. | 335,000 | $365,150 | 0.47% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,973,683 | $2,151,314 | 0.25% |
Monashee Investment Management LLC | 427,265 | $465,719 | 0.20% |
Orbimed Advisors | 7,133,515 | $7,775,531 | 0.16% |
Parkman Healthcare Partners LLC | 800,000 | $872,000 | 0.16% |